Medicare Coverage In Brief
This article was originally published in The Gray Sheet
Executive SummaryNo coverage for PET infection Dx: CMS will maintain its noncoverage policy for fluorodeoxyglucose-positron emission tomography (PET) scans to diagnose chronic osteomyelitis (bone infection), infection from hip arthroplasty and fevers of unknown origin, it said March 19. The agency cites inadequate data, "including heterogeneity of cases, lack of consistent comparators, small samples sizes, missing data ... and poor methodologic structure." CMS decided against employing a coverage-with-evidence-development policy because nobody proposed a clinical study that would fulfill the requirements, the agency said. CMS already covers PET for diagnosing certain cancers and conditionally covers PET for other indications, including Alzheimer's, dementia and other cancers
You may also be interested in...
Smith & Nephew launches orthobiologics spinout. CMS proposes CED for wound care gel. More news briefs.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.